Bicycle Therapeutics (NASDAQ:BCYC) Issues Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC) announced its quarterly earnings data on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.63, Briefing.com reports. Bicycle Therapeutics had a negative return on equity of 50.10% and a negative net margin of 404.14%. The firm had revenue of $19.53 million during the quarter, compared to the consensus estimate of $6.06 million. The company’s revenue for the quarter was up 298.9% compared to the same quarter last year.

Bicycle Therapeutics Trading Down 0.4 %

BCYC opened at $24.58 on Friday. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $28.91. The business’s 50-day moving average price is $24.02 and its 200-day moving average price is $19.47. The company has a current ratio of 8.08, a quick ratio of 8.08 and a debt-to-equity ratio of 0.08.

Analyst Ratings Changes

Several analysts have issued reports on BCYC shares. Canaccord Genuity Group restated a “buy” rating and issued a $60.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.86.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,158 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the sale, the chief executive officer now owns 387,270 shares in the company, valued at $9,220,898.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 5,312 shares of company stock worth $126,139 in the last ninety days. 10.20% of the stock is owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.